BIOATLA, INC. (BCAB) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 25.46M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 3.99M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -32.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.46M | (m) | $3.99M | $-32.13M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $35.80M | (m) | $4.75M | $-51.00M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $43.57M | (m) | $5.43M | $-59.30M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $47.23M | (m) | $6.25M | $-66.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $54.08M | (m) | $7.15M | $-63.77M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $56.60M | (m) | $8.27M | $-67.10M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $63.09M | (m) | $8.92M | $-73.94M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $74.12M | (m) | $9.73M | $-86.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $86.12M | (m) | $11.05M | $-109.98M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $100.89M | (m) | $12.23M | $-125.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $103.73M | (m) | $13.54M | $-129.69M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $102.93M | (m) | $14.31M | $-129.71M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $94.37M | (m) | $14.38M | $-120.87M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $84.12M | (m) | $14.54M | $-112.72M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $79.35M | (m) | $14.56M | $-108.14M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-09-30 | $73.92M | $0.00 | $14.87M | $-103.07M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $70.64M | $0.00 | $15.65M | $-100.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $64.77M | (m) | $24.11M | $-101.99M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $58.27M | $300.00K | $25.12M | $-96.44M | $3.00K | 19424.67% | 8372.33% | -32146.67× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $19.93M | (m) | $3.02M | $-30.10M | $1.39M | (m) | (m) | -21.67× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $25.92M | (m) | $0.00 | $-28.27M | $1.63M | (m) | (m) | -17.34× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |